Responses and durable stable disease were observed across multiple solid tumor types including gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, ovarian cancer, alveolar sarcoma, and urothelial cancer in both PD-1–naive patients and those with prior anti–PD-1 exposure. This evidence concerns the gene PDCD1 and ovarian cancer.